CG Oncology Insiders Land Bargain With Gains Of US$3.8m
CG Oncology Insiders Land Bargain With Gains Of US$3.8m
Insiders who bought CG Oncology, Inc. (NASDAQ:CGON) stock lover the last 12 months are probably not as affected by last week's 13% loss. Even after accounting for the recent loss, the US$5.06m worth of stock purchased by them is now worth US$8.85m or in other words, their investment continues to give good returns.
在過去的12個月裏，買入了CG Oncology，Inc.(納斯達克:CGON)的內部人士可能不會受到上週13%的虧損影響。即使考慮到最近的虧損，他們購買的價值爲506萬美元的股票現在價值爲885萬美元，換句話說，他們的投資仍然帶來良好的收益。
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.
雖然我們絕不建議投資者僅基於公司董事所做的事情來作出決策，但我們認爲密切關注內部人士所做的事情是完全合理的。
CG Oncology Insider Transactions Over The Last Year
CG Oncology上一年的內幕交易情況
In the last twelve months, the biggest single purchase by an insider was when Independent Director Hong Fang Song bought US$5.0m worth of shares at a price of US$19.00 per share. We do like to see buying, but this purchase was made at well below the current price of US$33.20. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.
在過去的十二個月中，一位獨立董事洪芳松大規模買入了價值500萬美元的股票，購買價爲每股19.00美元。我們確實喜歡看到購買，但這次購買價格遠低於目前的股價33.20美元。因爲這些股票是以較低的價格購買的，這次購買並不能告訴我們內部人士對於當前股票價格的看法。
While CG Oncology insiders bought shares during the last year, they didn't sell. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!
雖然CG Oncology內部人士在過去一年中購買了股票，但他們並沒有出售。您可以在下面看到內幕交易（由公司和個人）過去12個月的視覺表示。點擊下面的圖表，您可以查看每一筆內部交易的詳細信息！
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.
還有很多其他的公司，公司的內部人士正在購買股票。你可能不想錯過這個免費的小市值公司的低估列表。
Does CG Oncology Boast High Insider Ownership?
CG Oncology擁有高內部持股嗎？
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. CG Oncology insiders own 7.1% of the company, currently worth about US$162m based on the recent share price. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.
查看公司內部人員持股總額可以幫助您判斷他們是否與普通股東利益相一致。通常情況下，內部人員持股越高，越有可能激勵內部人員爲長期發展而努力。CG Oncology的內部人員持有公司的7.1％，目前根據最近的股價，價值約爲16200萬美元。這種內部人員的重大持股通常會增加公司爲所有股東利益而運行的機會。
What Might The Insider Transactions At CG Oncology Tell Us?
CG Oncology的內幕交易會給我們帶來什麼提示？
It doesn't really mean much that no insider has traded CG Oncology shares in the last quarter. On a brighter note, the transactions over the last year are encouraging. It would be great to see more insider buying, but overall it seems like CG Oncology insiders are reasonably well aligned (owning significant chunk of the company's shares) and optimistic for the future. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing CG Oncology. When we did our research, we found 3 warning signs for CG Oncology (1 is potentially serious!) that we believe deserve your full attention.
在過去的一個季度中沒有內部人士交易CG Oncology的股票並沒有實質意義。好消息是，過去一年的交易是令人鼓舞的。我們很想看到更多內部人員買入，但總體來說，CG Oncology的內部人員擁有大量公司股份，對未來持樂觀態度並且相當統一。除了了解正在進行的內部交易，識別CG Oncology面臨的風險也是有益的。我們進行研究時，發現CG Oncology有3個警告信號（其中1個可能非常嚴重！）值得您完全關注。
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
如果您想查看另一家公司的信息-一家潛在具有優秀財務狀況的公司-請不要錯過這個帶有高股權回報率和低債務的有趣公司免費列表。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
對於本文而言，內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置，但不包括衍生交易或間接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋？對內容有任何疑慮？請直接與我們聯繫。或者，發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論，只使用公正的方法論，我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議，也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意，我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有任何反饋？對內容有任何疑慮？請直接與我們聯繫。或者，發送電子郵件至editorial-team@simplywallst.com。
譯文內容由第三人軟體翻譯。